查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1990215

可待因市場：依產品類型、劑型、應用、通路和最終用戶分類－2026-2032年全球市場預測

Codeine Market by Product Type, Form, Application, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，可待因市場價值將達到 43.1 億美元，到 2026 年將成長至 45 億美元，到 2032 年將達到 59.8 億美元，複合年成長率為 4.79%。

主要市場統計數據
基準年 2025 43.1億美元
預計年份：2026年 45億美元
預測年份：2032年 59.8億美元
複合年成長率 (%) 4.79%

可待因作為醫療保健領域治療手段的全面概述，包括其概述、臨床作用、監管複雜性、安全問題以及不斷變化的相關人員期望。

可待因在現代臨床實踐中佔據複雜而重要的地位，它長期以來一直被用作鎮痛藥和止咳藥，同時也是監管和公共衛生措施的重點關注對象。臨床上，可待因的藥理特性及其在複方製劑中的應用使其在多種疼痛管理和止咳適應症中保持著廣泛的作用。然而，其代謝特性以及患者反應的潛在差異性要求在複方製劑中對其進行謹慎管理。近年來，衛生部門和醫生更加重視風險降低、患者選擇以及適合不同年齡層的製劑選擇，尤其是在兒童和老年人群中。

本文詳細回顧了受更嚴格的監管、替代療法、供應穩定性和製劑趨勢驅動的可待因市場格局的關鍵變化。

可待因領域正經歷許多變革，這些變革正在重塑臨床實踐、供應鏈結構和監管參與方式。多個司法管轄區加強監管，提高了製劑、標籤和上市後監測的標準，促使生產商和臨床醫生優先考慮風險管理措施和循證合理用藥方案。同時，針對特定適應症的替代療法和非鴉片類藥物的推廣，正在改變製劑趨勢，更加注重多方面的疼痛管理方法以及在臨床適用情況下使用非鴉片類鎮咳藥。

評估 2025 年美國關稅措施對可待因供應鏈、原料藥採購成本、臨床應用和生產的累積影響。

美國2025年實施的關稅措施對全球可待因生態系統產生了累積性影響，促使籌資策略發生累積，活性成分（API）採購成本差異顯現，並促使企業重新評估庫存和製造地。影響關鍵中間體和成品進口的關稅變化，促使製造商考慮近岸外包和供應商多元化，以確保供應的連續性，同時也提升了垂直整合生產能力的戰略價值。為此，採購團隊正在擴展供應商合格流程，並加強供應商績效監控，以保護臨床用藥免受暫時性貿易摩擦的影響。

透過細分洞察，揭示產品類型、配方選擇、臨床應用、分銷管道和最終用戶環境等方面的需求模式。

細分市場分析揭示了不同的需求因素和臨床要求如何轉化為差異化的產品開發和分銷策略。依產品類型分類，硫酸可待因、磷酸可待因、硫酸可待因和複方製劑之間的差異決定了化學原料的採購管道、製劑的適用性以及監管文件的結構。複方製劑通常需要額外的動態和安全性驗證。按劑型分類，注射劑、糖漿和片劑之間的動態影響著臨床應用案例和供應鏈的選擇。注射劑的需求受肌肉注射和靜脈注射兩個細分市場的影響，這兩個細分市場對無菌性和低溫運輸的要求各不相同。糖漿的選擇受含糖和無糖選項的影響，這與患者的人口統計特徵和標籤要求有關。另一方面，片劑必須在緩釋和速效之間取得平衡，以滿足鎮痛方案的要求。

區域比較分析揭示了監管差異、獲取臨床服務的挑戰、供應鏈脆弱性以及推動策略重點的需求趨勢。

區域趨勢對可待因製劑的監管、供應和臨床應用有深遠影響，區域差異既影響短期因應措施，也影響長期策略。在美洲，法律規範和醫療服務體系導致集中採購與製劑多樣化並存的局面，因此供應商的可靠性和分銷責任至關重要。在歐洲、中東和非洲，管理體制分散、報銷環境各異，加上對藥物安全監測的高期望，因此需要製定兼顧區域差異的監管策略，並進行嚴格的上市後監測。在亞太地區，醫療基礎設施的快速擴張和區域間生產能力的差異為本土生產創造了機遇，同時也需要統一品質標準，以實現跨境供應。

公司對創新策略、產品組合多元化、生產適應性和夥伴關係的洞察，塑造了競爭激烈的可待因市場。

可待因市場的企業層面趨勢反映了創新、營運柔軟性和遵守日益嚴格的監管要求之間的平衡。主要企業和學名藥生產商優先考慮產品組合多元化和製劑創新，以在解決安全問題和滿足患者偏好的同時，保持其臨床意義。對無糖糖漿製劑、兒童劑型和緩釋片的策略性投資表明，產品設計如何能夠降低特定臨床風險，並提高某些患者群體的用藥依從性。

業界領導者運用這些極具影響力和可操作性的建議，在平衡患者用藥、監管合規、供應穩定和負責任的鴉片類藥物管理方面發揮重要作用。

為了在應對日益成長的安全期望和供應不確定性的同時，保障患者獲得治療，行業領導者應採取一系列切實有效的措施。加強供應商網路並確保原料藥的替代來源，將降低單一來源風險，並為應對貿易政策或物流問題時靈活調整生產策略創造空間。同時，投資研發多樣化的製劑，例如無糖糖漿、兒童用藥和緩釋片，將使產品線能夠與不斷變化的臨床指南和患者需求保持一致。這些投資，加上強化藥物監測系統以及與監管機構的積極合作，必須確保附加檔和使用說明反映最新的實證醫學證據。

透過結合與主要相關人員的訪談、監管審查、臨床證據的整合和多方面的檢驗，調查方法提供了可操作的見解。

本分析的研究基礎是將與關鍵相關人員的對話、監管審查、臨床證據整合以及嚴謹的多方面檢驗相結合，從而得出可操作的見解。關鍵資訊來源包括與臨床醫生、監管專家、供應鏈經理和銷售代表的結構化訪談，這些訪談捕捉了實際營運和新興的臨床模式。研究人員系統性地審查了監管文件、臨床指南和同行評審文獻，並根據當前的護理標準和安全預期進行解釋。整合這些資訊使得研究人員能夠交叉檢驗臨床趨勢、藥物偏好和分銷趨勢。

結論：整合臨床、監管、供應鏈和商業性要求，以決定目前的治療用途和適當的用途優先事項。

總之，可待因製劑的治療和商業性前景受多種因素的複雜影響，包括監管力度加大、臨床替代方案不斷湧現、供應鏈持續存在漏洞，以及需要謹慎管理以最大限度減少不良反應。應對這些因素需要製定一項綜合策略，將產品設計、供應鏈和與臨床醫生的合作相結合，從而在確保安全用藥的同時，降低濫用風險。法律規範的不斷演變和貿易趨勢對採購和定價的影響，積極調整其生產、採購和臨床支持模式的相關人員將更有利於維持穩定的供應和臨床意義。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 可待因市場：依產品類型分類

  • 硫酸可待因
  • 磷酸可待因
  • 硫酸可待因
  • 組合配方

第9章：可待因市場：以劑型分類

  • 注射藥物
    • 肌肉內部
    • 靜脈
  • 糖漿
    • 糖
    • 無醣
  • 藥片
    • 緩釋
    • 立即生效

第10章：可待因市場：依應用領域分類

  • 止咳藥
  • 疼痛管理
    • 急性疼痛
    • 慢性疼痛

第11章 可待因市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 可待因市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第13章 可待因市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 可待因市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 可待因市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國可待因市場

第17章：中國的可待因市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Accord Healthcare by Intas Pharmaceuticals
  • Advik Pharma
  • AstraEureka Pharmaceuticals
  • Bristol Laboratories Limited
  • Crescent Pharma Limited
  • Johnson Matthey Plc
  • Noramco, Inc.
  • Omnica Laboratories
  • Pfizer Inc.
  • Professional Compounding Centers of America, Inc.
  • SANOFI WINTHROP INDUSTRIE
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-99555D550530

The Codeine Market was valued at USD 4.31 billion in 2025 and is projected to grow to USD 4.50 billion in 2026, with a CAGR of 4.79%, reaching USD 5.98 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.31 billion
Estimated Year [2026] USD 4.50 billion
Forecast Year [2032] USD 5.98 billion
CAGR (%) 4.79%

Comprehensive overview of codeine therapeutics, clinical roles, regulatory complexities, safety concerns, and evolving stakeholder expectations in healthcare

Codeine occupies a complex and consequential position within contemporary therapeutic practice, serving as both a long-established analgesic and antitussive agent and a focal point for regulatory scrutiny and public health policy. Clinically, codeine's pharmacologic profile and its inclusion in combination products have sustained its role across a range of pain management and cough suppression indications, while its metabolism and potential for variable patient response have driven careful stewardship in prescribing. Over recent years, health authorities and prescribers have intensified emphasis on risk mitigation, patient selection, and age-appropriate formulations, particularly where pediatric and elderly populations are concerned.

As a result, manufacturers, clinicians, and distributors operate in an environment where supply continuity, formulation innovation, and compliance with divergent national regulations converge. This environment demands a layered understanding of product variants, permissible formulations, and the interplay between clinical utility and safety obligations. Transitional technologies such as tele-prescribing, combined with evolving pharmacovigilance expectations, are changing how codeine products are accessed and monitored. Consequently, stakeholders must balance therapeutic access with robust mitigation of misuse and diversion risks while maintaining operational resilience across manufacturing and distribution channels.

In-depth review of major shifts reshaping the codeine landscape driven by regulatory tightening, therapeutic substitution, supply resilience and prescribing

The landscape for codeine is undergoing several transformative shifts that are redefining clinical practice, supply chain architecture, and regulatory engagement. Regulatory tightening in multiple jurisdictions has elevated the standards for prescribing, labeling, and post-market surveillance, prompting manufacturers and clinicians to prioritize risk management measures and evidence-based stewardship programs. Concurrently, therapeutic substitution and the expansion of non-opioid alternatives for specific indications have altered prescribing trajectories, encouraging greater emphasis on multimodal pain management pathways and non-opioid antitussives where clinically appropriate.

Supply chain resilience has become a strategic imperative as raw material controls, geopolitical tensions, and logistic bottlenecks expose vulnerabilities in active pharmaceutical ingredient sourcing and finished product distribution. At the same time, innovation in formulations-ranging from sugar-free syrups to extended-release tablets and combination products-reflects both patient-centric demands and regulatory accommodation for safer dosing. Digital tools for prescribing, adverse-event monitoring, and adherence support are gaining traction, aligning clinical decision-making with real-world safety data. Together, these shifts are creating a healthcare ecosystem in which manufacturers, payers, and providers must coordinate to ensure therapeutic access while meeting heightened expectations for safety, transparency, and supply continuity.

Evaluation of cumulative effects from United States tariff actions in 2025 on codeine supply chains, API sourcing costs, clinical access, and manufacturing

United States tariff actions implemented in 2025 have exerted a cumulative effect on the global codeine ecosystem by redirecting sourcing strategies, exposing cost differentials in active pharmaceutical ingredient procurement, and prompting reassessments of inventory and manufacturing footprints. Tariff changes affecting key intermediates and finished product imports have encouraged manufacturers to evaluate nearshoring and supplier diversification as mechanisms to protect supply continuity, while also increasing the strategic value of vertically integrated production capabilities. In response, procurement teams have expanded supplier qualification processes and intensified supplier performance monitoring to insulate clinical supply from episodic trade friction.

Clinicians and health systems have experienced indirect consequences through procurement cycles and formulary reviews, leading to an increased preference for products with stable supply chains and transparent provenance. Pharmaceutical manufacturers have accelerated conversations on domestic production capacity, contract manufacturing partnerships, and API substitution where scientific and regulatory frameworks permit. Regulatory authorities and trade policymakers have, in some cases, instituted exemptions or expedited review pathways for essential medicines to preserve clinical access, and private-sector actors have adopted hedging strategies in inventory management to mitigate near-term disruptions. The net effect is a recalibration of operational priorities where trade policy, clinical continuity, and production agility intersect.

Segmentation insights revealing demand patterns across product types, formulation options, clinical applications, distribution channels and end-user settings

Segmentation analysis reveals how heterogeneous demand drivers and clinical requirements translate into differentiated product development and distribution strategies. Based on product type, distinctions among Codeine Hydrochloride, Codeine Phosphate, Codeine Sulfate, and Combination Products determine chemical sourcing pathways, formulation compatibility, and regulatory dossier composition, with combination products often requiring additional pharmacodynamic and safety demonstration. Based on form, the dynamics between Injection, Syrup, and Tablet formats influence clinical use cases and supply chain choices; Injection demand is shaped by intramuscular and intravenous subsegments that impose distinct sterility and cold-chain requirements, Syrup offerings are influenced by sugar based and sugar free choices tied to patient populations and labeling expectations, while Tablet formats must balance extended release and immediate release profiles to meet analgesic regimens.

Based on application, differentiation between Cough Suppression and Pain Management carries implications for age segmentation and dosing strategies; cough suppression pathways further divide into adult formulations and pediatric formulations that require separate clinical and regulatory attention, and pain management splits into acute pain and chronic pain pathways that demand tailored benefit-risk assessments. Based on distribution channel, the roles of Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy affect inventory management, prescription validation, and patient counseling practices. Finally, based on end user, clinics, home care, and hospitals each present unique procurement behaviors and clinical governance frameworks that must be addressed through targeted commercial and clinical strategies to ensure appropriate access and oversight.

Regional comparative insights exposing regulatory variation, clinical access challenges, supply chain fragility, and demand trends guiding strategic priorities

Regional dynamics exert a persistent influence on how codeine products are regulated, supplied, and used in clinical practice, and variations by geography shape both short-term responses and long-term strategies. In the Americas, regulatory frameworks and healthcare delivery systems create a mix of centralized procurement and diverse prescribing practices, producing a landscape in which supplier reliability and distribution accountability are highly valued. In Europe, Middle East & Africa, fragmentation across regulatory regimes and heterogenous reimbursement environments combine with strong pharmacovigilance expectations to require regionally nuanced regulatory strategies and rigorous post-market monitoring. In Asia-Pacific, rapid expansion of healthcare infrastructure and varying degrees of local manufacturing capacity have produced both opportunities for domestic production and the need to harmonize quality standards to enable cross-border supply.

Across these regions, supply chain resilience, regulatory alignment, and clinical stewardship priorities diverge in emphasis but converge on shared objectives: preserving safe therapeutic access, ensuring traceable supply chains, and mitigating misuse. Strategic decisions regarding manufacturing footprint, regulatory submissions, and distribution partnerships must therefore be informed by region-specific constraints and enablers. Effective regional strategies incorporate local regulatory engagement, tailored clinical education initiatives, and commercially feasible logistics arrangements, enabling stakeholders to reconcile global product strategies with the operational realities of each geography.

Company insights into innovation strategies, portfolio diversification, manufacturing adaptability and partnerships shaping the competitive codeine landscape

Company-level dynamics in the codeine landscape reflect a balance between innovation, operational flexibility, and compliance with tightening regulatory requirements. Leading manufacturers and generic producers have prioritized portfolio diversification and formulation innovation to retain clinical relevance while addressing safety concerns and patient preferences. Strategic investments in sugar free syrup formulations, pediatric-appropriate dosing forms, and extended-release tablets demonstrate how product design can mitigate certain clinical risks and improve adherence across specific patient cohorts.

At the same time, manufacturing adaptability and supply chain transparency have emerged as core competitive differentiators. Companies that have invested in multi-sourced APIs, GMP-compliant facilities, and validated contract manufacturing partnerships are better positioned to navigate procurement disruptions and policy shifts. Commercial strategies increasingly emphasize collaborative relationships with healthcare systems, pharmacovigilance data sharing, and targeted clinical education to support appropriate use. Partnerships with contract research and manufacturing organizations enable faster scale-up and flexibility, while proprietary formulation know-how and robust quality systems sustain regulatory readiness and market access.

High-impact, pragmatic recommendations for industry leaders to balance patient access, regulatory compliance, supply security, and responsible opioid stewardship

To sustain therapeutic access while meeting heightened safety expectations and supply uncertainties, industry leaders should pursue a set of pragmatic, high-impact actions. Strengthening supplier networks and qualifying alternative API sources will reduce single-source risk and create room for agile manufacturing responses when trade policies or logistics issues arise. Concurrently, investing in formulation diversification-such as developing sugar free syrups, pediatric-friendly doses, and controlled-release tablets-aligns product offerings with evolving clinical guidance and patient needs. These investments should be coupled with enhanced pharmacovigilance systems and active collaboration with regulators to ensure labeling and usage guidance reflect best available evidence.

Commercially, organizations should prioritize transparent communication with healthcare providers and payers to build confidence in product quality and continuity. This includes targeted education programs on responsible prescribing, adverse-event reporting, and appropriate substitution where applicable. Operationally, leaders should consider capacity-building in contract manufacturing relationships and regional production hubs to buffer against external shocks. Finally, governance mechanisms that integrate compliance, clinical stewardship, and supply planning into executive decision-making will support balanced outcomes that preserve patient access while limiting misuse and diversion.

Methodology combining primary stakeholder interviews, regulatory review, clinical evidence synthesis, and multi-source validation to deliver actionable insights

The research underlying this analysis combines primary stakeholder engagement, regulatory review, clinical evidence synthesis, and rigorous multi-source validation to produce actionable findings. Primary inputs included structured interviews with clinicians, regulatory specialists, supply chain managers, and commercial leaders to capture operational realities and emergent practice patterns. Regulatory documents, clinical guidelines, and peer-reviewed literature were systematically reviewed to ground interpretation in current standards of care and safety expectations. Synthesis of these inputs enabled triangulation of clinical trends, formulation preferences, and distribution behaviors.

Data quality controls included cross-validation of interview findings against published guidance and manufacturing standards, and iterative expert feedback to refine interpretations and recommendations. Segmentation and regional analyses were constructed to align product, form, application, distribution, and end-user perspectives with geographic regulatory environments. The methodology prioritized transparency in assumptions and traceability of sources, enabling readers to follow the evidentiary basis for conclusions and to request tailored analyses aligned with specific commercial or operational questions.

Conclusion synthesizing clinical, regulatory, supply chain, and commercial imperatives that will shape near-term therapeutic use and stewardship priorities

In summary, the therapeutic and commercial trajectory for codeine products is shaped by intersecting forces: intensified regulatory scrutiny, evolving clinical alternatives, persistent supply chain vulnerabilities, and the need for prudent stewardship to minimize harm. These forces require integrated strategies that align product design, supply architecture, and clinician engagement to maintain safe access while reducing potential for misuse. As regulatory frameworks continue to evolve and trade dynamics exert influence on sourcing and pricing behavior, stakeholders who proactively adapt their manufacturing, procurement, and clinical support models will be best positioned to sustain reliable supply and clinical relevance.

Looking ahead, effective responses will combine investment in formulation and manufacturing flexibility with robust pharmacovigilance and targeted education for prescribers and patients. Embedding these approaches within corporate governance and regional operational plans will enable organizations to reconcile public health obligations with commercial viability. The imperative is clear: a coordinated, evidence-based approach that safeguards patient access while strengthening the resilience and accountability of the codeine supply chain will define success in the near term.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Codeine Market, by Product Type

  • 8.1. Codeine Hydrochloride
  • 8.2. Codeine Phosphate
  • 8.3. Codeine Sulfate
  • 8.4. Combination Products

9. Codeine Market, by Form

  • 9.1. Injection
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
  • 9.2. Syrup
    • 9.2.1. Sugar Based
    • 9.2.2. Sugar Free
  • 9.3. Tablet
    • 9.3.1. Extended Release
    • 9.3.2. Immediate Release

10. Codeine Market, by Application

  • 10.1. Cough Suppression
  • 10.2. Pain Management
    • 10.2.1. Acute Pain
    • 10.2.2. Chronic Pain

11. Codeine Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Codeine Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care
  • 12.3. Hospitals

13. Codeine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Codeine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Codeine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Codeine Market

17. China Codeine Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Accord Healthcare by Intas Pharmaceuticals
  • 18.7. Advik Pharma
  • 18.8. AstraEureka Pharmaceuticals
  • 18.9. Bristol Laboratories Limited
  • 18.10. Crescent Pharma Limited
  • 18.11. Johnson Matthey Plc
  • 18.12. Noramco, Inc.
  • 18.13. Omnica Laboratories
  • 18.14. Pfizer Inc.
  • 18.15. Professional Compounding Centers of America, Inc.
  • 18.16. SANOFI WINTHROP INDUSTRIE
  • 18.17. Sun Pharmaceutical Industries Ltd.
  • 18.18. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CODEINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CODEINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CODEINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CODEINE MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CODEINE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CODEINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CODEINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CODEINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CODEINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CODEINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CODEINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CODEINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CODEINE MARKET SIZE, BY CODEINE HYDROCHLORIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CODEINE MARKET SIZE, BY CODEINE HYDROCHLORIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CODEINE MARKET SIZE, BY CODEINE HYDROCHLORIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CODEINE MARKET SIZE, BY CODEINE PHOSPHATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CODEINE MARKET SIZE, BY CODEINE PHOSPHATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CODEINE MARKET SIZE, BY CODEINE PHOSPHATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CODEINE MARKET SIZE, BY CODEINE SULFATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CODEINE MARKET SIZE, BY CODEINE SULFATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CODEINE MARKET SIZE, BY CODEINE SULFATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CODEINE MARKET SIZE, BY COMBINATION PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CODEINE MARKET SIZE, BY COMBINATION PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CODEINE MARKET SIZE, BY COMBINATION PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CODEINE MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CODEINE MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CODEINE MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CODEINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CODEINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CODEINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CODEINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CODEINE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CODEINE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CODEINE MARKET SIZE, BY SYRUP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CODEINE MARKET SIZE, BY SYRUP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CODEINE MARKET SIZE, BY SYRUP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CODEINE MARKET SIZE, BY SUGAR BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CODEINE MARKET SIZE, BY SUGAR BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CODEINE MARKET SIZE, BY SUGAR BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CODEINE MARKET SIZE, BY SUGAR FREE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CODEINE MARKET SIZE, BY SUGAR FREE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CODEINE MARKET SIZE, BY SUGAR FREE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CODEINE MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CODEINE MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CODEINE MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CODEINE MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CODEINE MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CODEINE MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CODEINE MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CODEINE MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CODEINE MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CODEINE MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CODEINE MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CODEINE MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CODEINE MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CODEINE MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CODEINE MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CODEINE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CODEINE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CODEINE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CODEINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CODEINE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CODEINE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CODEINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CODEINE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CODEINE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CODEINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CODEINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CODEINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CODEINE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CODEINE MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CODEINE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CODEINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CODEINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CODEINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CODEINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS CODEINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CODEINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. GCC CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 175. GCC CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 177. GCC CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 178. GCC CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. GCC CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 180. GCC CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. GCC CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. G7 CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 205. G7 CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 206. G7 CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 207. G7 CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 208. G7 CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. G7 CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 210. G7 CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. G7 CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. NATO CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 215. NATO CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 216. NATO CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 217. NATO CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 218. NATO CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. NATO CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 220. NATO CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. NATO CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES CODEINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA CODEINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)